logo
VKTX_logo
Phase 1 Study of Dual GLP-1/GIP Agonist VK2735 Continues to Enroll: Data Expected in Early 2023. In early 2022, Viking announced the initiation of a Phase 1 clinical trial of VK2735 for the potential treatment of various metabolic disorders. VK2735 is a dual agonist of the glucagon like peptide-1, or GLP-1 receptor, and the glucose dependent insulinotropic polypeptide, or GIP, receptor.

Viking Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter and nine months ended September 30, 2022, and provided an update on its clinical pipeline and other corporate developments

By AP News
Published - Oct 26, 2022, 05:38 PM ET
Last Updated - Apr 24, 2024, 02:06 PM EDT

Conference call scheduled for 4:30 p.m. ET today

  • Company Positioned to Announce Data from Three Clinical Programs in 2023
  • VK2809 Phase 2b VOYAGE Study On Track to Complete Enrollment in Q4 2022; Data Expected in 1H 2023
    • Article Source
    Quick Links
    Categories
    Our Offices
    • 10kInfo, Inc.
      13555 SE 36th St
      Bellevue, WA 98006
    • 10kInfo Data Solutions, Pvt Ltd.
      Claywork Create
      11 km, Arakere Bannerghatta Rd, Omkar Nagar, Arekere,
      Bengaluru, Karnataka 560076
    4.2 12182024